

Supplementary Online Content

Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment study: a randomized clinical trial. *JAMA Cardiol*. Published online April 5, 2017.
doi:10.1001/jamacardio.2017.0175

eTable 1. ViDA CVD Outcomes Based on Ministry of Health Hospital Discharge (A* and B# codes) and Dispensed Prescription Data: Primary End Point I10-I82

eTable 2. Hazard Ratios of Cardiovascular Disease During Follow-up Associated With Baseline 25-Hydroxyvitamin D (25(OH)D) Concentration and Demographic Variables in the Placebo Group, Adjusted for All Other Variables in the Table

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. ViDA CVD Outcomes Based on Ministry of Health Hospital Discharge (A* and B# codes) and Dispensed Prescription Data: Primary End Point I10-I82

Description	ICD 10 Code	New disease or acute events
Hypertension	I10-I15	Not on treatment for hypertension at baseline AND (A or B code) AND No (A or B code) for other CVD
Angina pectoris	I20	No history of angina at baseline AND <ul style="list-style-type: none"> • (A or B code) OR • initiation of nitrate (> 1 prescription) after baseline
Acute myocardial infarction (MI)	I21	<ul style="list-style-type: none"> • A code (regardless of past history) • B Code AND no history of MI at baseline
Subsequent MI	I22	A code only
Chronic ischaemic heart disease	I25	A code only
Pulmonary embolism	I26	A code only
Other pulmonary heart diseases	I27	A code only
Pericarditis, valvular, endocarditis & myositis	I30.1, I31 to I41	A code only
Cardiomyopathy	I25.5, I42.0, I42.7, I42.8, I42.9	No history of heart failure at baseline AND (A or B code)
Conduction disorders	I44, I45	A code only
Cardiac arrest	I46	A code only
Arrhythmias	I47-I49	A code only
Heart failure	I11.0, I50.0, I50.1, I50.9	No history of heart failure at baseline AND <ul style="list-style-type: none"> • (A or B code) OR • initiation of loop diuretics (> 1 prescription) after baseline
Ill-defined heart disease	I51	A code only
Cerebral haemorrhage	I61,I62	No history of stroke at baseline AND (A or B code)
Cerebral infarction	I63	No history of stroke at baseline AND (A or B code)

Other stroke (excl. haemorrhage)	I64-I67	No history of stroke at baseline AND (A or B code)
Diseases of the arteries, etc	I70-I79	A code only
Diseases of the veins (incl. venous thrombosis)	I80-I82	A code only

* A code = primary reason for hospitalization or death

B codes = secondary reasons for hospitalization or death

eTable 2. Hazard Ratios of Cardiovascular Disease During Follow-up Associated With Baseline 25-Hydroxyvitamin D (25(OH)D) Concentration and Demographic Variables in the Placebo Group, Adjusted for All Other Variables in the Table

Variable	Hazard Ratio (95% CI)	P-value (Wald Chi-square)
Age (years)		
50-59	1.00	<0.0001
60-69	1.50 (1.01, 2.24)	
70-79	3.67 (2.49, 5.42)	
80-84	7.61 (4.80, 12.1)	
Sex		
Male	1.50 (1.16, 1.93)	0.002
Female	1.00	
Ethnicity		
Maori	1.89 (1.15, 3.11)	0.002
Pacific Islander	2.10 (1.33, 3.32)	
South Asian	1.23 (0.68, 2.22)	
Other	1.00	
Baseline 25(OH)D, ng/mL ^a		
<10	2.88 (1.65, 5.05)	0.002
10-<20	1.16 (0.84, 1.60)	
20-<30	1.03 (0.78, 1.36)	
≥30	1.00	

^a Based on deseasonalized concentrations.